GDS Holdings Limited ADS

Go to GDS Holdings Limited ADS Website

$8.50

(%)
Live
Previous Close

$8.5

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$1.6 billion USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfe...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

SHANGHAI, China, April 29, 2024 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission (the “SEC”) on April 29, 2024 U.S. Eastern Time.

Related tickers: GDS.

Read Full Article

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Consumer discretionary shares jumped by 0.6% on Monday. In trading on Monday, utilities shares fell by 1%.   Top Headline   TD SYNNEX Corporation (NYSE: SNX) reported better-than-expected first-quarter earnings. The company reported first quarter adjusted earnings per share of $2.99, beating the street view of $2.84. The company reported quarterly revenue of $13.975 billion, missing the analyst view of $14.357 billion.   Equities Trading UP   Stoke Therapeutics, Inc. (NASDAQ: STOK) shares shot up 72% to $11.19 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Shares of Mesoblast Ltd (NASDAQ: MESO) got a boost, surging 66% to $3.6420 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to ...

Related tickers: SNX, APCX, OPGN, MESO, GDS, CDLX, STOK.

Read Full Article
Trending Tickers
DATS

XNAS

$1.25
(%)
LASE

XNAS

$2.05
(%)
NYCB

XNYS

$2.79
(%)
PACW

XNAS

$7.54
(%)
MLGO

XNAS

$0.00
(%)